Health Ministry Amends Medical Devices Rules to Boost Ease of Business

India's Health Ministry has amended Medical Devices Rules, 2017, to boost Ease of Doing Business. The reforms remove the loan license requirement for outsourced sterilisation and add the EU to the clinical trial waiver list for faster market entry.

India's Union Ministry of Health and Family Welfare has officially rolled out targeted amendments to the Medical Devices Rules, 2017, designed to boost Ease of Doing Business (EoDB), eliminate regulatory bottlenecks, and accelerate consumer access to advanced healthcare tech.

Major Amendments to Medical Devices Rules

The reforms introduce two major structural shifts for manufacturers and importers- loan licensing axed for outsourced sterilisation (Rule 44), and EU added to the clinical trial waiver list (Rule 63). Manufacturers using third-party sterilisation facilities (provided those facilities hold a valid license under the 2017 Rules) no longer need to apply for a separate loan license. Eliminating this step slashes administrative duplication, compliance costs, and manufacturing timelines, particularly for med-tech startups and smaller manufacturers lacking in-house sterilisation infrastructure. Traceability requirements remain intact to preserve safety standards, and a six-month transition period has been granted for updating product labelling and packaging. The European Union now joins the US, UK, Australia, Canada, and Japan as a recognised stringent regulatory jurisdiction. Medical devices lacking predicate devices in India that already hold EU approval can now qualify for clinical investigation waivers. This significantly shortens the runway for bringing cutting-edge European medical technology into the Indian market.

Summary of Key Changes

Outsourced sterilisation: Rule 44 amended to drop the loan license requirement, eliminating dual-licensing costs and cutting pre-market prep time.

EU regulatory recognition: Rule 63 expanded to include the European Union for faster market entry for EU-approved devices via clinical trial waivers.

Labelling Compliance: 6-month grace period for packaging updates for smooth operational transition without supply chain disruptions.

By aligning domestic oversight with global benchmarks, these amendments reduce cost burdens while maintaining strict safety, quality, and performance standards across the medical device sector. (ANI)

(Except for the headline, this story has not been edited by Asianetnews Editorial staff and is published from a syndicated feed.)